All In Biotech

Investigational drug · Phase 2

AMXI-5001

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer.

Phase 2

Last checked: Nov 20, 2026Latest source record: May 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "AMXI-5001"

First trial start

2020

Aug 12, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AMXI-5001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Malignant Neoplasm
  • Breast Cancer
  • Ovarian Cancer
  • Homologous Recombination Deficiency
  • Prostate Cancer
  • Pancreatic Cancer

Approved drugs for the same conditions: Breast cancer · Prostate cancer · Ovarian cancer · Pancreatic cancer · Oncology · Rare and genetic disease · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "AMXI-5001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Advanced Malignant Neoplasm

  • IAP0971Phase 23 trials

    SUNHO(China)BioPharmaceutical CO., Ltd. · Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer

  • QLF31907Phase 21 trial

    Qilu Pharmaceutical Co., Ltd. · Advanced Malignant Neoplasm

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.